Table 1 Demographics and baseline disease characteristics
SVR at LPVPS | No SVR at LPVPS | ||
|---|---|---|---|
N = 200 | Eligible N = 294 | Enrolled N = 49 | |
Age, years; median (range) | 52.0 (22–70) | 53.0 (19–71) | 56.0 (28–70) |
≤ 45 years, n (%) | 61 (30.5) | 64 (21.8) | 7 (14.3) |
> 45 − ≤ 65 years, n (%) | 133 (66.5) | 218 (74.1) | 38 (77.6) |
> 65 years, n (%) | 6 (3.0) | 12 (4.1) | 4 (8.2) |
Male, n (%) | 122 (61.0) | 196 (66.7) | 32 (65.3) |
Ethnicity, n (%) | |||
Hispanic or Latino | 7 (3.5) | 35 (11.9) | 5 (10.2) |
Race, n (%)a | |||
White | 187 (93.5) | 268 (91.2) | 44 (89.8) |
Black/African American | 8 (4.0) | 21 (7.1) | 4 (8.2) |
American Indian/Alaskan native | 1 (0.5) | 0 | 0 |
Asian | 4 (2.0) | 3 (1.0) | 1 (2.0) |
Native Hawaiian or other Pacific islander | 0 | 2 (0.7) | 0 |
IL28B genotype, n/N (%)b | |||
CC | 10/34 (29.4) | 9/143 (6.3) | 0 |
CT | 19/34 (55.9) | 99/143 (69.2) | 17/20 (85.0) |
TT | 5/34 (14.7) | 35/143 (24.5) | 3/20 (15.0) |
Prior response, n (%)a | |||
Naïve | 50 (25.0) | 138 (46.9) | 15 (30.6) |
Null responder | 26 (13.0) | 46 (15.6) | 12 (24.5) |
Partial responder | 48 (24.0) | 38 (12.9) | 9 (18.4) |
Relapser | 76 (38.0) | 72 (24.5) | 13 (26.5) |
Baseline HCV RNA, log10 IU/mL; median (range)a | 6.44 (3.5–7.5) | 6.62 (4.9–7.6) | 6.76 (5.6–7.5) |
LPVPS HCV RNA, log10 IU/mL; median (range) a,c | 0.95 (1.0–1.0) | 6.35 (3.2–7.4) | 6.35 (3.2–7.4) |
HCV geno/subtypea | |||
1a/other | 68 (34.0) | 174 (59.2) | 25 (51.0) |
with Q80K | 21 (30.9) | 79 (45.4) | 10 (40.0) |
1b | 132 (66.0) | 120 (40.8) | 24 (49.0) |
METAVIR fibrosis score; n/N (%)a,d | |||
F0, 1 or 2 | 152/199 (76.4) | 156/290 (53.8) | 27/49 (55.1) |
F3 | 26/199 (13.1) | 76/290 (26.2) | 8/49 (16.3) |
F4 | 21/199 (10.6) | 58/290 (20.0) | 14/49 (28.6) |